BIOLASE, Inc., the global leader in dental lasers, announced a strategic plan to partner with postgraduate dental specialty programs throughout North America, to expose new dentists to the benefits of Waterlase technology.
Waterlase Dental Laser Adoption Expected to Grow Among Dental Residency Programs
LAKE FOREST, Calif., Aug. 31, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced a strategic plan to partner with postgraduate dental specialty programs throughout North America, to expose new dentists to the benefits of Waterlase technology.
In the U.S., there are approximately 700 postgraduate residency programs. The programs range from one to four years and are general dentistry and specialty programs.
“If you are familiar with the technology adoption life cycle, we are in the early adopter’s phase,” stated John Casciano, Sales Director of Special Markets for BIOLASE. “We believe investing in postgraduate programs will accelerate the adoption curve and be mutually beneficial. The residents will learn the benefits of all tissue laser technology in dentistry while providing the latest in patient care.”
“During the second quarter of 2022, we integrated our Waterlase lasers into several postgraduate programs and plan to continue this growth and integration over the next few years. There is a large appetite among dental residents to utilize state-of-the-art technology in treating patients. This is the first generation of dentists raised with new technologies as a normal part of their everyday lives,” said Casciano.
Dr. Sam Low, Professor Emeritus from the University of Florida, agrees. He added, “The introduction and reinforcement of technology during postgraduate training is key to adoption of laser dentistry with the new generation of dentists. Technology was a valued part of dentistry when I began practicing, but technology is mandatory for today’s modern dental practitioner.”
The Waterlase dental laser offers an array of benefits for dentists and their patients—from faster procedures to less invasive treatment options. Educating postgraduate residents about the benefits of dental lasers is part of BIOLASE’s continued effort to help improve patient experiences and outcomes, and raise significant awareness as to the advantages of laser dentistry.
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 302 patented and 31 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2021, BIOLASE has sold over 43,300 laser systems in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE’s expected revenue and revenue growth and beliefs regarding its financial resources. Forward-looking statements can be identified through the use of words such as “may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s most recent annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-announces-development-of-strategic-plan-to-partner-with-postgraduate-dental-specialty-programs-across-the-us-301614933.html
SOURCE BIOLASE, Inc.
Company Codes: NASDAQ-SMALL:BIOL
